Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Lymphoid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 40Leukemia, Myeloid, Chronic-Phase 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Leukemia 5Blast Crisis 5Neoplasm Metastasis 3Melanoma 3Leukemia, Myeloid, Acute 3Gastrointestinal Stromal Tumors 3Synovitis, Pigmented Villonodular 2Recurrence 2Leukemia, Myeloid, Accelerated Phase 2Substance Withdrawal Syndrome 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Neurofibromatoses 1Neurofibroma, Plexiform 1Neurofibroma 1Neoplasms 1Neoplasm, Residual 1Mucosal Lentiginous Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1Head and Neck Neoplasms 1Glioma 1Giant Cell Tumor of Tendon Sheath 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Chordoma 1Carcinoma, Squamous Cell 1

Interventions

Cyclophosphamide 115Dexamethasone 70fludarabine phosphate 57Cytarabine 56fludarabine 52Rituximab 51Peripheral Blood Stem Cell Transplantation 40Etoposide 40Gemcitabine 39Lenalidomide 38pembrolizumab 33Radiotherapy 33Busulfan 33Filgrastim 32Carboplatin 31Methotrexate 30Cyclosporine 29Cisplatin 29Bortezomib 29Mycophenolic Acid 28Melphalan 28venetoclax 27Paclitaxel 26Whole-Body Irradiation 24Antilymphocyte Serum 23Temozolomide 22Granulocyte Colony-Stimulating Factor 20Calcium Dobesilate 20Bevacizumab 20Tacrolimus 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Recurrence × nilotinib × Clear all
NCT01774630 2026-05-26

NiloPost-STIM

University Hospital, Bordeaux

Phase 2 Completed
31 enrolled
MyeloidOther hematologic neoplasm

Recurrence, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00036738 2020-01-29

Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib

Fred Hutchinson Cancer Center

Phase 2 Completed
28 enrolled 10 charts
LymphoidMyeloidOther hematologic neoplasm

Blast Crisis, Recurrence, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡